1. Fujiki T, Ando F, Mandai S, Isobe K, Susa K, Mori T, Nomura N, Sohara E, Rai T, Uchida S.. Tolvaptan and Bardoxolone Methyl Synergistically Activate the Nrf2/HO-1 pathway.. ASN Kidney Week 2019 2019.11.08

  1. Tamami Fujiki, Fumiaki Ando, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tolvaptan activates Nrf2/HO-1 pathway through PERK phosphorylation. The 52nd Annual Meeting of American Society of Nephrology, Kidney Week 2018 2018.10.26 San Diego

  1. Soichiro Iimori, Shotaro Naito, Hidehiko Sato, Naohiro Nomura, Eisei Sohara, Tomokazu Okado, Shinichi Uchida, Tatemitsu Rai. Effects of proteinuria reduction on kidney function, mortality and cardiovascular risk in newly visiting CKD patients in Japan : the CKD-ROUTE study. The 6th CKD Frontier Meeting 2017.02.25 Nagoya, Japan

  1. Soichiro Iimori, Hidenori Nishida, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida, Sei Sasaki.. Anemia management and cardiovascular risk in newly visited CKD patients in Japan. The 14th Asian Pacific Congress of Nephrology 2014.05.15

  1. Fujiki T, Ando F, Mandai S, Isobe K, Susa K, Mori T, Nomura N, Sohara E, Rai T, Uchida S. Tolvaptan activates the Nrf2/HO-1 pathway through PERK phosphorylation. The 23nd International Joint Conference on Cardiovascular and Metabolic diseases 2019.12.14

  2. Fujiki T, Ando F, Isobe K, Susa K, Mori T, Nomura N, Sahara E, Rai T, Uchida S. Tolvaptan activates the Nrf2/HO-1 pathway through PERK phosphorylation. The 62nd Annual Meeting of the Japanese Society of Nephrology 2019.06.22 Nagoya

To the head of this page.▲